Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676646 · ClinicalTrials.gov registry record · Phase 4
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 366
- Enrollment target
NCT04676646 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 366 participants.
The verdict
NCT04676646, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 366 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue therapy for hyperkalaemia (HK).
Interventions
- DRUG Placebo
- DRUG Sodium zirconium cyclosilicate
- OTHER Spironolactone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2024-07-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04676646
The ClinicalTrials.gov registry entry for NCT04676646 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04676646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04676646 about?
NCT04676646 is a clinical study titled "Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone". The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue therapy for hyperkalaemia (HK).
What is the current status of trial NCT04676646?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 366 participants. The study started on 2021-03-08. Estimated completion is 2024-07-15.
What interventions are being tested in trial NCT04676646?
The interventions under investigation include: Placebo (DRUG), Sodium zirconium cyclosilicate (DRUG), Spironolactone (OTHER).
Who is sponsoring clinical trial NCT04676646?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.